DE19612966B4 - MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren - Google Patents
MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren Download PDFInfo
- Publication number
- DE19612966B4 DE19612966B4 DE19612966A DE19612966A DE19612966B4 DE 19612966 B4 DE19612966 B4 DE 19612966B4 DE 19612966 A DE19612966 A DE 19612966A DE 19612966 A DE19612966 A DE 19612966A DE 19612966 B4 DE19612966 B4 DE 19612966B4
- Authority
- DE
- Germany
- Prior art keywords
- cells
- infection
- influenza viruses
- cell
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 60
- 230000001902 propagating effect Effects 0.000 title claims description 6
- 238000004113 cell culture Methods 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 36
- 239000000725 suspension Substances 0.000 claims abstract description 19
- 239000012679 serum free medium Substances 0.000 claims abstract description 10
- 230000012010 growth Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims description 60
- 241000700605 Viruses Species 0.000 claims description 59
- 230000010412 perfusion Effects 0.000 claims description 25
- 102000004142 Trypsin Human genes 0.000 claims description 23
- 108090000631 Trypsin Proteins 0.000 claims description 23
- 239000012588 trypsin Substances 0.000 claims description 22
- 230000000644 propagated effect Effects 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 239000004365 Protease Substances 0.000 claims description 12
- 101710154606 Hemagglutinin Proteins 0.000 claims description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 8
- 101710176177 Protein A56 Proteins 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000000185 hemagglutinin Substances 0.000 claims description 7
- 238000010923 batch production Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 210000000605 viral structure Anatomy 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 1
- 108700010900 influenza virus proteins Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 154
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 38
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012770 revaccination Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000845082 Panama Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229950005033 alanosine Drugs 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- -1 lipoid fractions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19612966A DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| CA002250714A CA2250714C (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| AT97915627T ATE482267T1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
| EP97915627A EP0904351B1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| EP10075278A EP2275535A1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| JP53508997A JP4243349B2 (ja) | 1996-04-01 | 1997-04-01 | インフルエンザウイルスの複製のための動物細胞および方法 |
| US09/155,581 US6455298B1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| ES97915627T ES2352638T3 (es) | 1996-04-01 | 1997-04-01 | Células animales y procedimientos de replicación del virus de la gripe. |
| DE69740002T DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
| PCT/IB1997/000403 WO1997037000A1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| HK99104226.0A HK1019233B (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| DK97915627.0T DK0904351T3 (da) | 1996-04-01 | 1997-04-01 | Dyreceller og fremgangsmåder til replikationen af influenzavirus |
| PT97915627T PT904351E (pt) | 1996-04-01 | 1997-04-01 | Células animais e processos para a replicação de vírus influenza |
| US10/194,784 US6656720B2 (en) | 1996-04-01 | 2002-07-12 | Animal cells and processes for the replication of influenza viruses |
| JP2004233905A JP2004331673A (ja) | 1996-04-01 | 2004-08-10 | インフルエンザウイルスの複製のための動物細胞および方法 |
| US11/057,370 US20050202553A1 (en) | 1996-04-01 | 2005-02-15 | Animal cells and processes for the replication of influenza viruses |
| JP2005108075A JP2005211080A (ja) | 1996-04-01 | 2005-04-04 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2006147486A JP2006230415A (ja) | 1996-04-01 | 2006-05-26 | インフルエンザウイルスの複製のための動物細胞および方法 |
| US12/146,689 US20080274141A1 (en) | 1996-04-01 | 2008-06-26 | Animal cells and processes for the replication of influenza viruses |
| JP2008287206A JP2009034115A (ja) | 1996-04-01 | 2008-11-07 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2011192118A JP2012005502A (ja) | 1996-04-01 | 2011-09-02 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2011224914A JP2012016358A (ja) | 1996-04-01 | 2011-10-12 | インフルエンザウイルスの複製のための動物細胞および方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19655438 | 1996-04-01 | ||
| DE19612966A DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19612966A1 DE19612966A1 (de) | 1997-10-02 |
| DE19612966B4 true DE19612966B4 (de) | 2009-12-10 |
Family
ID=7790126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19612966A Expired - Fee Related DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE69740002T Expired - Lifetime DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69740002T Expired - Lifetime DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6455298B1 (https=) |
| EP (2) | EP2275535A1 (https=) |
| JP (7) | JP4243349B2 (https=) |
| AT (1) | ATE482267T1 (https=) |
| DE (2) | DE19612966B4 (https=) |
| DK (1) | DK0904351T3 (https=) |
| ES (1) | ES2352638T3 (https=) |
| PT (1) | PT904351E (https=) |
| WO (1) | WO1997037000A1 (https=) |
Families Citing this family (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| ES2248920T3 (es) * | 1997-10-25 | 2006-03-16 | Roche Diagnostics Gmbh | Lineas celulares de encapsidacion en suspension para vectores retrovirales. |
| ATE356197T1 (de) | 1997-12-24 | 2007-03-15 | Duphar Int Res | Herstellung von zellen für die produktion von biologischen produkten |
| JP4698112B2 (ja) * | 2000-03-03 | 2011-06-08 | 一般財団法人化学及血清療法研究所 | 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法 |
| JP3547715B2 (ja) * | 2001-03-06 | 2004-07-28 | 榮 新垣 | ベクター精製用装置及び方法 |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| US20030078471A1 (en) * | 2001-10-18 | 2003-04-24 | Foley Frederick J. | Manipulation of an organ |
| US6951752B2 (en) * | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| ES2526191T3 (es) * | 2002-04-26 | 2015-01-08 | Medimmune, Llc | Método para producir virus influenza B infeccioso en cultivo celular |
| US7465456B2 (en) * | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| US7262045B2 (en) * | 2003-02-25 | 2007-08-28 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| AU2004249802B2 (en) * | 2003-06-20 | 2007-06-28 | Microbix Biosystems Inc. | Improvements in virus production |
| JPWO2005026333A1 (ja) * | 2003-09-09 | 2006-11-16 | 独立行政法人科学技術振興機構 | プロテアーゼを用いた接着性細胞の浮遊培養技術、及び該細胞を宿主として用いてウイルスを生産する方法 |
| ATE469972T1 (de) * | 2003-12-23 | 2010-06-15 | Medimmune Llc | Multiplasmid-system zur erzeugung des grippevirus |
| WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
| CA2562932A1 (en) * | 2004-04-01 | 2005-10-27 | Alza Corporation | Apparatus and method for transdermal delivery of influenza vaccine |
| NZ551640A (en) * | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| JP2008512443A (ja) | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| JP5147405B2 (ja) | 2004-10-06 | 2013-02-20 | メディミューン，エルエルシー | 冷蔵温度安定型インフルエンザワクチン組成物 |
| DE102004049290A1 (de) * | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
| EP2923711A1 (en) * | 2004-11-03 | 2015-09-30 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
| ES2536745T3 (es) | 2004-12-08 | 2015-05-28 | Medimmune, Llc | Métodos de producción de composiciones de vacuna contra la gripe |
| ATE547511T1 (de) | 2004-12-23 | 2012-03-15 | Medimmune Llc | Nichttumorbildende mdck-zellinie zur vermehrung von viren |
| US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
| CA2627971A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
| EP3753574A1 (en) * | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
| WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| US7883844B2 (en) | 2006-05-11 | 2011-02-08 | Juridical Foundation The Chemosero-Therapeutic Research Institute | Method for propagating influenza virus |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| ES2536401T3 (es) * | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| WO2008105931A2 (en) | 2006-09-15 | 2008-09-04 | Medimmune Vaccines, Inc. | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| CA2690196A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
| EA201070066A1 (ru) * | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| WO2009023562A2 (en) * | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| WO2009115917A2 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
| TW201012930A (en) * | 2008-06-16 | 2010-04-01 | Intervet Int Bv | Method of replicating viruses in suspension |
| MY172788A (en) | 2008-08-01 | 2019-12-12 | Gamma Vaccines Pty Ltd | Influenza vaccines |
| RU2547587C2 (ru) | 2008-09-24 | 2015-04-10 | Медиммун, Ллк | Способы культивирования клеток, размножения и очистки вирусов |
| CN102215865B (zh) | 2008-09-24 | 2013-10-30 | 米迪缪尼有限公司 | 病毒纯化方法 |
| WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
| CA2750055A1 (en) | 2009-02-06 | 2010-08-12 | Glaxosmithkline Biologicals S.A. | Method for purifying viruses using a density gradient |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| AU2010212548A1 (en) | 2009-02-10 | 2011-09-15 | Novartis Ag | Influenza vaccines with increased amounts of H3 antigen |
| FR2949344A1 (fr) | 2009-04-27 | 2011-03-04 | Novartis Ag | Vaccins de protection contre la grippe |
| JP5740392B2 (ja) | 2009-05-08 | 2015-06-24 | ノバルティス アーゲー | インフルエンザウイルスを検出するための一般的なアッセイ |
| EP2573184A1 (en) | 2009-05-21 | 2013-03-27 | Novartis AG | Reverse genetics using non-endogenous POL I promoters |
| EA201171491A1 (ru) | 2009-05-29 | 2012-07-30 | Новартис Аг | Анализы гемагглютининов вируса гриппа |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| CN102741399A (zh) * | 2009-10-20 | 2012-10-17 | 诺华有限公司 | 用于病毒拯救的改良反向遗传方法 |
| EP2493912B1 (en) | 2009-10-26 | 2020-07-29 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
| EP2506832B1 (en) | 2009-12-03 | 2014-02-26 | Novartis AG | Hydrophilic filtration during manufacture of vaccine adjuvants |
| DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| RS52748B (sr) | 2009-12-03 | 2013-08-30 | Novartis Ag | Cirkulacija komponenti tokom homogenizacije emulzija |
| JP5751678B2 (ja) | 2009-12-03 | 2015-07-22 | ノバルティス アーゲー | マイクロフルイダイゼーションのための相互作用チャンバおよび背圧チャンバの構成 |
| WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| ES2528010T5 (es) | 2010-03-08 | 2018-02-19 | Novartis Ag | Métodos para detectar la presencia de patógenos intracelulares |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US20130039943A1 (en) | 2010-05-03 | 2013-02-14 | Bruno Rene Andre | Novel method |
| WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
| SG185419A1 (en) | 2010-05-12 | 2012-12-28 | Novartis Ag | Improved methods for preparing squalene |
| AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
| EP2575872B1 (en) | 2010-06-01 | 2020-08-19 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| SG187863A1 (en) * | 2010-08-16 | 2013-03-28 | Cevec Pharmaceuticals Gmbh | Permanent human amniocyte cell lines for producing influenza viruses |
| US9051361B2 (en) | 2010-08-17 | 2015-06-09 | National Health Research Institutes | Immunogenic compositions and uses thereof |
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| US9657359B2 (en) | 2010-09-07 | 2017-05-23 | Novartis Ag | Generic assays for detection of mamalian reovirus |
| US20140079732A1 (en) | 2011-01-27 | 2014-03-20 | Gamma Vaccines Pty Limited | Combination vaccines |
| US9580761B2 (en) | 2011-02-25 | 2017-02-28 | Novartis Ag | Exogenous internal positive control |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| WO2013088367A1 (en) | 2011-12-12 | 2013-06-20 | Novartis Ag | Assay for influenza virus hemagglutinins |
| EP2820126B1 (en) * | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
| AU2014203051C1 (en) * | 2012-03-02 | 2016-09-01 | Seqirus UK Limited | Influenza Virus Reassortment |
| RU2599496C2 (ru) | 2012-03-06 | 2016-10-10 | Круселл Холланд Б.В. | Улучшенная вакцинация против гриппа |
| JP6152535B2 (ja) * | 2012-04-16 | 2017-06-28 | 公益財団法人ヒューマンサイエンス振興財団 | 細胞培養組成物及びインフルエンザウイルスの生産方法 |
| WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| KR20150110494A (ko) | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| HK1218511A1 (zh) | 2013-03-13 | 2017-02-24 | Novartis Ag | 乙型流感病毒重配 |
| EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| CA2914604A1 (en) | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
| KR101370512B1 (ko) | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| US9950057B2 (en) | 2013-07-15 | 2018-04-24 | Wisconsin Alumni Research Foundation (Warf) | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
| US10392603B2 (en) | 2013-08-30 | 2019-08-27 | The Chemo-Sero-Therapeutic Research Institute | Method of viral purification |
| AU2014350370B2 (en) | 2013-11-15 | 2017-04-13 | Novartis Ag | Removal of residual cell culture impurities |
| TW202204596A (zh) | 2014-06-06 | 2022-02-01 | 美商健臻公司 | 灌注培養方法及其用途 |
| TWI776235B (zh) * | 2014-06-09 | 2022-09-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| MA40920A (fr) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci |
| ES2721306T3 (es) | 2014-12-02 | 2019-07-30 | Novartis Ag | Fabricación de composiciones que contienen tensioactivo |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| HK1254344A1 (zh) | 2015-06-26 | 2019-07-19 | Seqirus UK Limited | 抗原匹配的流感疫苗 |
| WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| HUE051783T2 (hu) | 2015-07-07 | 2021-03-29 | Seqirus Uk Ltd | Eljárás immunogén hemagglutinin mennyiségi meghatározására |
| TWI830290B (zh) * | 2015-10-30 | 2024-01-21 | 財團法人國家衛生研究院 | 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株 |
| CA3014435C (en) | 2016-02-19 | 2023-04-18 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza b virus replication for vaccine development |
| JP6933643B2 (ja) | 2016-03-29 | 2021-09-08 | 一般財団法人阪大微生物病研究会 | Ｍｄｃｋ細胞の培養方法 |
| JP2017038622A (ja) * | 2016-11-21 | 2017-02-23 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| MX2020004543A (es) | 2017-11-03 | 2020-09-18 | Takeda Vaccines Inc | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| EP3965811A1 (en) | 2019-05-08 | 2022-03-16 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN116171166A (zh) | 2020-06-30 | 2023-05-26 | 塞其里斯英国有限公司 | 水包油乳液佐剂的冷过滤 |
| US20250381261A1 (en) | 2022-02-09 | 2025-12-18 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| CN116376810A (zh) * | 2023-04-26 | 2023-07-04 | 上海奥浦迈生物科技股份有限公司 | 一种mdck细胞无血清贴壁培养驯化的方法 |
| WO2025186793A1 (en) * | 2024-03-08 | 2025-09-12 | Seqirus Inc. | Culture methods for virally-infected cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616203A (en) * | 1969-12-11 | 1971-10-26 | Norden Lab Inc | Virus culture and method |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1278075B (de) * | 1964-06-22 | 1968-09-19 | Norden Lab Inc | Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen |
| US4064232A (en) | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| CA1122527A (en) | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
| US5013663A (en) * | 1983-06-15 | 1991-05-07 | American Home Products Corporation | Canine corona virus vaccine |
| US4783411A (en) | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
| ES2081864T3 (es) | 1989-03-29 | 1996-03-16 | Univ New York State Res Found | Metodo para purificar una proteina de la membrana exterior de haemophilus influenzae. |
| JP2827298B2 (ja) * | 1989-07-10 | 1998-11-25 | 三菱化学株式会社 | 細胞培養担体 |
| AT393277B (de) | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| JPH0420284A (ja) * | 1990-05-12 | 1992-01-23 | Mitsubishi Kasei Corp | 細胞培養用マイクロキャリア |
| JPH05207873A (ja) * | 1992-01-27 | 1993-08-20 | Mitsubishi Kasei Corp | 付着性動物細胞の培養方法 |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| ES2378409T3 (es) | 1994-11-10 | 2012-04-12 | Baxter Healthcare S.A. | Método para producir sustancias biológicas en cultivo sin proteínas |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5756341A (en) * | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| EP0808361A4 (en) | 1994-11-16 | 2001-07-18 | St Jude Childrens Res Hospital | Novel replication process |
| US5646033A (en) * | 1994-11-30 | 1997-07-08 | Dyncorp | African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines |
| AU712213B2 (en) | 1995-09-22 | 1999-11-04 | Connaught Laboratories Limited | Parainfluenza virus glycoproteins and vaccines |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| US6514502B1 (en) * | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
-
1996
- 1996-04-01 DE DE19612966A patent/DE19612966B4/de not_active Expired - Fee Related
-
1997
- 1997-04-01 EP EP10075278A patent/EP2275535A1/en not_active Withdrawn
- 1997-04-01 PT PT97915627T patent/PT904351E/pt unknown
- 1997-04-01 DE DE69740002T patent/DE69740002D1/de not_active Expired - Lifetime
- 1997-04-01 EP EP97915627A patent/EP0904351B1/en not_active Expired - Lifetime
- 1997-04-01 JP JP53508997A patent/JP4243349B2/ja not_active Expired - Fee Related
- 1997-04-01 DK DK97915627.0T patent/DK0904351T3/da active
- 1997-04-01 AT AT97915627T patent/ATE482267T1/de active
- 1997-04-01 US US09/155,581 patent/US6455298B1/en not_active Expired - Lifetime
- 1997-04-01 WO PCT/IB1997/000403 patent/WO1997037000A1/en not_active Ceased
- 1997-04-01 ES ES97915627T patent/ES2352638T3/es not_active Expired - Lifetime
-
2002
- 2002-07-12 US US10/194,784 patent/US6656720B2/en not_active Expired - Lifetime
-
2004
- 2004-08-10 JP JP2004233905A patent/JP2004331673A/ja not_active Withdrawn
-
2005
- 2005-02-15 US US11/057,370 patent/US20050202553A1/en not_active Abandoned
- 2005-04-04 JP JP2005108075A patent/JP2005211080A/ja not_active Withdrawn
-
2006
- 2006-05-26 JP JP2006147486A patent/JP2006230415A/ja not_active Withdrawn
-
2008
- 2008-06-26 US US12/146,689 patent/US20080274141A1/en not_active Abandoned
- 2008-11-07 JP JP2008287206A patent/JP2009034115A/ja not_active Withdrawn
-
2011
- 2011-09-02 JP JP2011192118A patent/JP2012005502A/ja not_active Withdrawn
- 2011-10-12 JP JP2011224914A patent/JP2012016358A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616203A (en) * | 1969-12-11 | 1971-10-26 | Norden Lab Inc | Virus culture and method |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
Non-Patent Citations (4)
| Title |
|---|
| Advances in "abstract" 1-32 CAPLUS experimental S.143, S.145 * |
| Advances in "abstract" 1-32 CAPLUS experimental S.143, S.145 Medicine and Biology Vol.397, 1996, S.141-151 Principles and techniques of practical biochemistry, 4. Aufl., ed, K. Wilson J. and J.M. Walker Cambridge University Press S. 21. ATCC Katalog "ATCC NummerCC2-34" |
| Medicine and Biology Vol.397, 1996, S.141-151 * |
| Principles and techniques of practical biochemistry, 4. Aufl., ed, K. Wilson J. and J.M. Walker Cambridge University Press S. 21. ATCC Katalog "ATCC NummerCC2-34" * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0904351T3 (da) | 2010-11-01 |
| WO1997037000A1 (en) | 1997-10-09 |
| DE69740002D1 (de) | 2010-11-04 |
| JP4243349B2 (ja) | 2009-03-25 |
| JP2000507448A (ja) | 2000-06-20 |
| JP2004331673A (ja) | 2004-11-25 |
| JP2006230415A (ja) | 2006-09-07 |
| PT904351E (pt) | 2010-12-28 |
| ES2352638T3 (es) | 2011-02-22 |
| ATE482267T1 (de) | 2010-10-15 |
| US6455298B1 (en) | 2002-09-24 |
| JP2012016358A (ja) | 2012-01-26 |
| JP2012005502A (ja) | 2012-01-12 |
| DE19612966A1 (de) | 1997-10-02 |
| JP2009034115A (ja) | 2009-02-19 |
| EP0904351B1 (en) | 2010-09-22 |
| EP2275535A1 (en) | 2011-01-19 |
| JP2005211080A (ja) | 2005-08-11 |
| HK1019233A1 (en) | 2000-01-28 |
| US20050202553A1 (en) | 2005-09-15 |
| EP0904351A1 (en) | 1999-03-31 |
| US6656720B2 (en) | 2003-12-02 |
| US20030073223A1 (en) | 2003-04-17 |
| US20080274141A1 (en) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19612966B4 (de) | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren | |
| DE10144906B4 (de) | Verfahren zur großtechnischen Herstellung von Impfstoffen | |
| EP1427817B1 (de) | Vermehrung von viren in zellkultur | |
| DE69732407T3 (de) | Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren | |
| DE60222296T2 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
| CA1144860A (en) | Compositions of matter | |
| DE19655440B4 (de) | Verfahren zur Herstellung eines Influenzaimpfstoffs | |
| CA2250714C (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1152546A (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1019233B (en) | Animal cells and processes for the replication of influenza viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE |
|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. K, DE |
|
| 8172 | Supplementary division/partition in: |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| Q171 | Divided out to: |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| AH | Division in |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| 8364 | No opposition during term of opposition | ||
| R082 | Change of representative |
Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE Representative=s name: UEXKUELL & STOLBERG, DE |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12N0005060000 Ipc: C12N0005070000 |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12N0005060000 Ipc: C12N0005070000 Effective date: 20120613 |
|
| R081 | Change of applicant/patentee |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG, 35041 MARBURG, DE Effective date: 20111209 |
|
| R082 | Change of representative |
Representative=s name: UEXKUELL & STOLBERG, DE Effective date: 20111209 Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE Effective date: 20111209 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |